false
0001293818
0001293818
2024-01-04
2024-01-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
January
4, 2024
Date of Report (date of earliest event reported)
_________________
OpGen, Inc.
(Exact name of Registrant as specified in its charter)
_________________
Delaware
(State or other jurisdiction of incorporation or
organization) |
|
001-37367
(Commission
File Number) |
|
06-1614015
(I.R.S. Employer
Identification Number) |
9717
Key West Ave, Suite 100
Rockville, MD
20850
(Address of principal executive offices)(Zip code)
(240) 813-1260
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_________________
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock |
OPGN |
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
In light of OpGen, Inc.’s (the “Company”)
focus on pursuing strategic alternatives and recent actions taken by its Board of Directors (the “Board”) to reduce the Company’s
executives’ base salaries by forty percent (40%), on January 4, 2024, the Board approved certain changes to its executives’
compensation in order to ensure the retention of key members of management while the Company continues to pursue a potential strategic
transaction or, in the absence of such a transaction, to enable the Company to seek bankruptcy protection. In furtherance of the foregoing,
the Board approved an increase in Oliver Schacht’s, the Company’s Chief Executive Officer, base salary to $300,000 from $244,800.
In addition, on January 8, 2024, the Company entered
into consulting agreements (each, a “Consulting Agreement”) with each of Albert Weber and Johannes Bacher, pursuant to which
Mr. Weber and Mr. Bacher will continue to serve as the Chief Financial Officer and Chief Operating Officer of the Company, respectively.
While Mr. Weber and Mr. Bacher are currently employed by the Company’s subsidiary Curetis GmbH (“Curetis”), as a result
of Curetis’ previously disclosed insolvency proceedings, the Company agreed to enter into the Consulting Agreements in order to
ensure Mr. Weber and Mr. Bacher continue to be compensated at the currently contemplated amounts. The Consulting Agreements provide that
each of Mr. Weber and Mr. Bacher will receive compensation of $25,000 per month (or $300,000 on an annualized basis) commencing in January
2024. Under the Consulting Agreements, the Company also agreed to pay each of Mr. Weber and Mr. Bacher an amount of $14,200 for the months
of November and December 2023, which amount reflects the difference between their then-current base salaries of $180,000 and the amounts
permitted to be paid to them by Curetis while it remained subject to the ongoing insolvency proceedings. The Consulting Agreements provide
that the Company will reimburse the executives for approved out-of-pocket expenses incurred in performing services for the Company.
The Consulting Agreements continue for a term of six
months and may be terminated earlier by either the Company or the applicable executive upon thirty (30) days prior written notice. The
Consulting Agreements contain other customary representations, warranties and covenants of the executives.
The foregoing description of the Consulting Agreements
does not purport to be complete and is qualified in its entirety by reference to the full text of the Consulting Agreements, which are
filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K and are incorporated herein by reference.
Item 9.01. Financial Statements
and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
Date: January 9, 2024 |
|
OpGen, Inc. |
|
|
|
|
|
|
By: |
|
/s/ Oliver Schacht |
|
|
|
|
Name: |
|
Oliver
Schacht, Ph.D. |
|
|
|
|
Title: |
|
Chief
Executive Officer |
Exhibit 10.1
|
9717 Key West Avenue,
Suite 100
Rockville, MD 20850 |
Phone 301-869-9683
Website www.OpGen.com |
Consultant
Name/Entity
|
Albert Weber |
OpGen Manager
|
Oliver Schacht |
Effective
Date
|
January 8, 2024 |
CONSULTING AGREEMENT
This Consulting Agreement (together
with its attachments, this “Agreement”) is entered into and effective as of the date written above (the “Effective
Date”) by and between OpGen, Inc. a Delaware corporation having an address at 9717 Key West Avenue, Suite 100, Rockville, MD,
20850 (“OpGen”), and the consultant named above and on the signature page (“Consultant”). OpGen
desires to have the benefit of Consultant’s knowledge and experience, and Consultant desires to provide Consulting Services (defined
below) to OpGen, all as provided in this Agreement.
1.
Consulting Services. OpGen retains Consultant and Consultant agrees to provide Consulting
Services to OpGen, including without limitation, serving as the chief financial officer of OpGen (the “Consulting Services”),
as it may from time to time reasonably request and as specified in the business terms exhibit attached to this Agreement (“Business
Terms Exhibit”). Any changes to the Consulting Services (and any related compensation adjustments) must be agreed upon in writing
between Consultant and OpGen prior to commencement of the changes.
1.1
Performance. Consultant agrees to render the Consulting Services to OpGen, or to its designee,
(i) at such reasonably convenient times and places as OpGen may direct, (ii) under the general supervision of OpGen, and (iii) on a best
efforts basis. Consultant will comply with all rules, procedures and standards promulgated from time to time by OpGen with regard to Consultant’s
access to and use of OpGen’s property, information, equipment and facilities. Consultant agrees to furnish OpGen with written reports
with respect to the Consulting Services if and when requested by OpGen.
1.2
Third Party Confidential Information. Consultant agrees not to use any trade secrets or other
confidential information of any other person, firm, corporation, institution or other entity in connection with any of the Consulting
Services.
1.3
No Conflicts. Consultant is under no contractual or other obligation or restriction which
is inconsistent with Consultant’s execution of this Agreement or the performance of the Consulting Services. During the Term (defined
below), Consultant will not enter into any agreement, either written or oral, in conflict with Consultant’s obligations under this
Agreement. Consultant will arrange to provide the Consulting Services in such manner and at such times that the Consulting Services will
not conflict with Consultant’s responsibilities under any other agreement, arrangement or understanding or pursuant to any employment
relationship Consultant has at any time with any third party.
1.4
Compliance with Policies. Consultant agrees to comply with all of the Company’s policies
and standards, as the Company may adopt from time to time, that are applicable to the Consultant, including without limitation, code of
ethics and business conduct and insider trading policies.
1.5
Absence of Debarment and other Disqualification. Consultant agrees and represents that neither
Consultant nor any Consultant Personnel (defined below) has (have) been debarred, and to the best of Consultant’s knowledge, is
(are) not under consideration to be debarred, by the U.S. Food and Drug Administration from working in or providing consulting services
to any pharmaceutical or biotechnology company under the Generic Drug Enforcement Act of 1992.
1.6
Other Representations and Warranties. Consultant represents and warrants that: (i)
Consultant has full right and power to enter into and perform this Agreement without the consent of any third party; (ii) Consultant will
comply with all laws and regulations applicable to Consultant’s obligations under this Agreement, will refrain from any unethical
conduct, and will maintain high standards of professionalism; and (ii) should OpGen permit Consultant to use any of OpGen’s equipment,
or facilities during the term of this Agreement, such permission shall be gratuitous and Consultant (a) shall be responsible for any injury
to any person (including death) or damage to property arising out of use of such equipment or facilities; and (b) shall perform all services
during OpGen’s normal business hours, unless OpGen otherwise specifically requests.
2.
Compensation. In consideration for the Consulting Services rendered by Consultant to OpGen,
OpGen agrees to pay Consultant the fees set forth in the Business Terms Exhibit attached hereto. Unless otherwise specified in the Business
Terms Exhibit, undisputed payments will be made by OpGen within thirty (30) days from OpGen’s receipt of Consultant’s complete
invoice. Invoices will contain such detail as OpGen may reasonably require and will be payable in U.S. Dollars in accordance with the
terms of the Business Terms Exhibit. OpGen will reimburse Consultant for reasonable and documented business expenses incurred by Consultant
in the performance of the Consulting Services as specified in the Business Terms Exhibit.
3.
Inventions.
3.1
Definition. “Inventions” means all inventions, discoveries, improvements,
ideas, designs, processes, products, computer programs, works of authorship, databases, mask works, trade secrets, know-how, research
and creations (whether or not patentable or subject to copyright or trade secret protection) that Consultant makes, conceives or reduces
to practice, either alone or jointly with others, and that (i) result from the performance of the Consulting Services, and/or (ii) result
from use of facilities, equipment, supplies, Research Materials (defined below), or Confidential Information (defined below) of OpGen.
3.2
Ownership. Consultant will promptly disclose all Inventions in confidence to OpGen. All Inventions
will be the exclusive property of OpGen. For purposes of the copyright laws of the United States, all Inventions will constitute “works
made for hire”, except to the extent such Inventions cannot by law be works made for hire. To the extent Inventions have not
been previously assigned to OpGen, Consultant hereby assigns and, to the extent any such assignment cannot be made at present, hereby
agrees to assign to OpGen, without further compensation, all right, title and interest in and to all Inventions and any and all related
patents, patent applications, copyrights, copyright applications, trademarks, trade names, trade secrets and other proprietary rights
in the United States and throughout the world. Consultant retains no rights to use the Inventions and agrees not to challenge the validity
of OpGen’s ownership in the Inventions. If Consultant has any right to the Inventions that cannot be assigned to OpGen by Consultant,
Consultant unconditionally and irrevocably grants to OpGen during the term of such rights, an exclusive, even as to Consultant, irrevocable,
perpetual, worldwide, fully paid and royalty-free license, with rights to sublicense through multiple levels of sublicensees, to reproduce,
make derivative works of, distribute, publicly perform and publicly display in any form or medium, whether now known or later developed,
make, use, sell, import, offer for sale and exercise any and all such rights. If Consultant has any rights to the Inventions that cannot
be assigned or licensed to OpGen, Consultant unconditionally and irrevocably waives the enforcement of such rights, and all claims and
causes of action of any kind against OpGen, an OpGen affiliate or licensee or related to OpGen’s customers, with respect to such
rights, and agrees, at OpGen’s request and expense, to consent to and join in any action to enforce such rights.
3.3
Assistance. Consultant agrees to assist OpGen in every way, both during and after the term
of this Agreement, to obtain and enforce United States and foreign intellectual property rights relating to Inventions in all countries.
In the event OpGen is unable to secure Consultant’s signature on any document needed in connection with such purposes, Consultant
hereby irrevocably designates and appoints OpGen and its duly authorized officers and agents as its agent and attorney in fact, which
appointment is coupled with an interest, to act on its behalf to execute and file any such documents and to do all other lawfully permitted
acts to further such purposes with the same legal force and effect as if executed by Consultant.
3.4
Research Materials. For Consulting Services which involve laboratory work or experiments,
“Research Materials” means all materials (i) furnished by OpGen, (ii) developed by Consultant in connection with the
Consulting Services, or (iii) the cost of which are reimbursed to Consultant by OpGen. Research Materials include, in the case of biological
materials, all progeny and unmodified derivatives of those materials, and in the case of chemical materials, all analogs, formulations,
mixtures and compositions of those materials. Research Materials are the sole property of OpGen. Consultant agrees not to use or evaluate
Research Materials for any purpose other than as directed by OpGen, nor transfer the Research Materials to any third party without the
prior consent of OpGen. Consultant will use the Research Materials in compliance with all laws and regulations.
3.5
Records. Consultant shall make and maintain adequate and current written records of all Inventions,
which records shall be available to and remain the property of OpGen at all times.
3.6
Agreement with Institution. This Agreement is made subject to the understanding that Consultant,
if affiliated with an Institution, may be required to fulfill certain obligations, including teaching, directing laboratory operations,
conducting research, and publishing work. It is further understood that Consultant may have signed an agreement concerning inventions
with Institution, under which Consultant may be obligated to assign to Institution certain inventions which arise out of or otherwise
relate to Consultant’s work at or for Institution or from Consultant’s use of certain of its facilities or intellectual property.
In performing the Consulting Services, Consultant agrees not to utilize Institution facilities or intellectual property if the result
of such use is that any Inventions will not be assignable solely to OpGen. Use of Institution’s telephone, fax machines or computers
for communication purposes, however, will not constitute use of Institution’s facilities under this Agreement.
3.7
Work at Third Party Facilities. Consultant agrees not to make any use of any funds, space,
personnel, facilities, equipment or other resources of a third party in performing the Consulting Services nor take any other action that
would result in a third party owning or having a right in any Inventions, unless agreed upon in writing in advance by OpGen.
4.
Confidential Information.
4.1
Definition. “Confidential Information” means any and all information disclosed
by OpGen to Consultant, or otherwise obtained by Consultant pursuant to services provided under this Agreement that is not generally known
in the Consultant’s trade or industry and shall include, without limitation, information with respect to the facilities and methods
of OpGen, Research Materials, trade secrets, Inventions, systems, patents and patent applications, procedures, manuals, confidential reports,
financial information, business plans, prospects, or opportunities, personnel information, lists of customers and suppliers, and information
of third parties provided by OpGen to Consultant. Confidential Information does not include information which (i) is in the public domain
or which becomes part of the public domain through no wrongful act on Consultant’s part but only after it becomes so publicly known,
(ii) is already in Consultant’s possession at the time of disclosure by OpGen, other than by previous disclosure by OpGen, as evidenced
by written or electronic records, or (iii) that becomes known to Consultant through disclosure by a third party having the right to disclose
the information, as evidenced by written or electronic records.
4.2
Obligations of Confidentiality. Consultant will not directly or indirectly publish, disseminate
or otherwise disclose, use for Consultant’s own benefit or for the benefit of a third party, deliver or make available to any third
party, any Confidential Information, other than in furtherance of the purposes of this Agreement, and only then with the prior written
consent of OpGen. If required, Consultant may disclose the Confidential Information to a governmental authority or by order of a court
of competent jurisdiction, provided that such disclosure is subject to all applicable governmental or judicial protection available for
like material and reasonable advance notice is given to OpGen. Consultant will exercise all reasonable precautions to physically protect
the integrity and confidentiality of the Confidential Information and will not remove any Confidential Information or copies thereof from
OpGen’s premises except to the extent necessary to fulfill the Consulting Services, and then only with OpGen’s prior consent.
Consultant may disseminate or permit access to Confidential Information only to Consultant Personnel who have a need to know such Confidential
Information in the course of the performance of their duties under this Agreement and who are bound to protect the confidentiality of
the Confidential Information consistent with the terms of this Agreement. OpGen will be entitled to seek injunctive relief as a remedy
for any breach of the terms of this Section 4.
5.
Restrictions. While Consultant is engaged by OpGen and for a period of eighteen (18) months
after the termination or cessation of the engagement for any reason, Consultant will not (i) provide consulting services to any business
or entity developing a product or sponsoring a project which competes with a product being developed or project being sponsored by OpGen
and for which Consultant is providing Consulting Services. It will not be considered a competitive activity for Consultant to be a member
of the faculty or staff of a university, college or other educational or non-profit research institution, nor (ii) recruit, solicit or
hire any consultants of OpGen or any person who was a consultant of OpGen during the twelve (12) month period prior to the termination
of Consultant’s engagement by OpGen, or induce or attempt to induce any of OpGen’s employees to terminate their employment
with, or otherwise cease their relationship with, OpGen or accept employment with anyone else.
6.
Publication. Consultant agrees to submit to OpGen a copy of any proposed manuscript or other
materials to be published or otherwise publicly disclosed which contain information or any discussion relating to OpGen or the Consulting
Services, in sufficient time in advance of such disclosure, to enable OpGen to determine if patentable Inventions or any Confidential
Information of OpGen would be disclosed. Consultant will cooperate with OpGen in this respect and will delete from the manuscript or other
disclosure any Confidential Information if requested by OpGen, and will assist OpGen in filing for patent protection for any patentable
Inventions prior to publication or other disclosure.
7.
Term and Termination.
7.1
Term. This Agreement will commence on the Effective Date and continue for the term specified
on the Business Terms Exhibit (the “Term”), unless sooner terminated pursuant to the express terms of this Section
7 or extended by mutual agreement of the parties.
7.2
Termination. Any party may terminate this Agreement at any time without cause upon thirty
(30) days’ prior written notice.
7.3
Termination for Breach. If either party breaches in any material respect any of its material
obligations under this Agreement, in addition to any other right or remedy the non-breaching party may have, the non-breaching party may
(i) terminate this Agreement effective immediate if the breach was not cured within fifteen (15) days after receipt of written notice
of the breach or (ii) immediately at any time upon written notice in the event of a material breach which cannot be cured (i.e.
breach of confidentiality obligation).
7.4
Effect of Expiration/Termination. Upon expiration or termination, neither OpGen nor Consultant
will have any further obligations under this Agreement, except (i) the liabilities accrued through the date of termination, and (ii) the
obligations under sections 3, 4, 5, 6, 7 and 8 will survive. Upon expiration or termination, and in any case upon OpGen’s request,
Consultant will at the sole discretion of OpGen either destroy or return immediately to OpGen all tangible Confidential Information, including
all copies and reproductions thereof, except for one (1) copy which may be retained solely for archival purposes.
8.
Miscellaneous.
8.1
Independent Contractor. All Consulting Services will be rendered by Consultant as an independent
contractor and this Agreement does not create an employer-employee relationship between OpGen and Consultant. Consultant will have no
rights to receive any employee benefits, such as health and accident insurance, sick leave or vacation which are accorded to regular OpGen
employees. Consultant will not in any way represent himself to be an employee, partner, joint venturer, or agent of OpGen. Consultant
is not authorized to make any representation, contract, or commitment on behalf of OpGen.
8.2
Taxes. Consultant will pay all required taxes on Consultant’s income from OpGen under
this Agreement. Consultant agrees to accept exclusive liability for complying with all applicable state and federal laws, including laws
governing self-employed individuals, if applicable, such as laws related to payment of taxes, social security, disability, and other contributions
based on fees paid to Consultant under this Agreement. OpGen will not withhold or make payments for social security, unemployment insurance
or disability insurance contributions, or obtain workers’ compensation insurance on Consultant’s behalf. Consultant will provide
OpGen with Consultant’s taxpayer identification number or social security number, as applicable.
8.3
Use of Name. Consultant consents to the use by OpGen of Consultant’s name and likeness
in written materials and oral presentations to current or prospective customers, partners, investors or others, provided that such materials
or presentations accurately describe the nature of Consultant’s relationship with or contribution to OpGen.
8.4
Assignability and Binding Effect. The Consulting Services to be rendered by Consultant are
personal in nature. Consultant may not assign or transfer this Agreement or any of Consultant’s rights or obligations hereunder
except to a corporation of which Consultant is the sole stockholder. In no event will Consultant assign or delegate responsibility for
actual performance of the Consulting Services to any other natural person except to Consultant Personnel as provided for under this Agreement.
This Agreement will be binding upon and inure to the benefit of the parties and their respective legal representatives, heirs, successors
and permitted assigns. OpGen may assign this Agreement to any other corporation or entity which acquires (whether by purchase, merger,
consolidation or otherwise) all or substantially all of the business and/or assets of OpGen.
8.5
Headings. The section headings are included solely for convenience of reference and will not
control or affect the meaning or interpretation of any of the provisions of this Agreement.
8.6
Notices. Any notices or other communications from one party to the other will be in writing
and will be given by addressing the same to the other at the address or facsimile number set forth in this Agreement. Notices to OpGen
will be marked “Attention: Chief Executive Officer”. Notice will be deemed to have been duly given when (i)
deposited in the United States mail with proper postage for first class registered or certified mail prepaid, return receipt requested,
(ii sent by any reputable commercial courier, delivery confirmation requested, (iii) delivered personally, or (iv) if promptly confirmed
by mail or commercial courier as provided above, when dispatched by facsimile.
8.7
No Modification. This Agreement may be changed only by a writing signed by authorized representatives
of both parties.
8.8
Severability. In the event that any one or more of the
provisions contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity,
illegality or unenforceability will not affect any other provisions of this Agreement, and all other provisions will remain in full
force and effect. If any provision of this Agreement is held to be excessively broad, it will be reformed and construed by limiting and
reducing it so as to be enforceable to the maximum extent permitted by law.
8.9
Entire Agreement. This Agreement constitutes the entire agreement of the parties with regard
to its subject matter, and supersedes all previous written or oral representations, agreements and understandings between the parties.
8.10
Governing Law. This Agreement will be governed by, and construed and enforced in accordance
with, the laws of the Federal Republic of Germany applicable to contracts made and to be performed therein, without giving effect to the
principles thereof relating to the conflict of laws.
8.11
Remedies. Consultant agrees that in addition to any other rights and remedies available to
OpGen for any breach or threatened breach by Consultant of Consultant’s obligations hereunder, OpGen will be entitled to enforcement
of Consultant’s obligations hereunder by whatever means are at OpGen’s disposal, including court injunction.
8.12
Counterparts. This Agreement may be executed in any number of counterparts, each of which
will be deemed an original, but all of which together will constitute one and the same instrument.
- Signatures on next page –
IN WITNESS WHEREOF, the parties hereto
have duly executed this Agreement under seal as of the Effective Date.
OpGen, Inc. |
Consultant/Entity:
|
/s/ William Rhodes
__________________________________________
Signature:
|
/s/ Albert Weber
__________________________________________
Signature:
|
William Rhodes, Chairman |
Printed Name: Albert Weber |
/s/ Oliver Schacht
_________________________________________
Signature:
Oliver Schacht, President & CEO |
|
January 8, 2024
__________________________________________
Date |
January 8, 2024
__________________________________________
Date |
|
Address: [**] |
|
________________________________________
Mobile:
[**]
__________________________________________
|
|
Facimile: NA
|
|
|
INSTITUTION
ACKNOWLEDGEMENT
AND CONSENT FORM
OpGen, Inc. (“OpGen”)
is prepared to enter into the foregoing Agreement with the consultant named on the preceding signature page (“Consultant”).
OpGen recognizes that as a member of the institution named below (“Institution”), Consultant is responsible for ensuring that
any consulting agreement Consultant enters into with a for-profit entity is not in conflict with the patent, consulting or other policies
of Institution. The proposed Agreement requires Consultant, if required by Institution policies, to disclose the proposed Agreement to
Institution and/or to obtain Institution’s consent to enter into the proposed Agreement.
Institution hereby acknowledges and
consents to Consultant entering into the foregoing Agreement.
INSTITUTION:
By ____________________
Print Name ____________________
Title
____________________
Date ____________________
Exhibit 10.2
|
9717 Key West Avenue,
Suite 100
Rockville, MD 20850 |
Phone 301-869-9683
Website www.OpGen.com |
Consultant
Name/Entity
|
Johannes Bacher |
OpGen Manager
|
Oliver Schacht |
Effective
Date
|
January 8, 2024 |
CONSULTING AGREEMENT
This Consulting Agreement (together
with its attachments, this “Agreement”) is entered into and effective as of the date written above (the “Effective
Date”) by and between OpGen, Inc. a Delaware corporation having an address at 9717 Key West Avenue, Suite 100, Rockville, MD,
20850 (“OpGen”), and the consultant named above and on the signature page (“Consultant”). OpGen
desires to have the benefit of Consultant’s knowledge and experience, and Consultant desires to provide Consulting Services (defined
below) to OpGen, all as provided in this Agreement.
1.
Consulting Services. OpGen retains Consultant and Consultant agrees to provide Consulting
Services to OpGen, including without limitation, serving as the chief operating officer of OpGen (the “Consulting Services”),
as it may from time to time reasonably request and as specified in the business terms exhibit attached to this Agreement (“Business
Terms Exhibit”). Any changes to the Consulting Services (and any related compensation adjustments) must be agreed upon in writing
between Consultant and OpGen prior to commencement of the changes.
1.1
Performance. Consultant agrees to render the Consulting Services to OpGen, or to its designee,
(i) at such reasonably convenient times and places as OpGen may direct, (ii) under the general supervision of OpGen, and (iii) on a best
efforts basis. Consultant will comply with all rules, procedures and standards promulgated from time to time by OpGen with regard to Consultant’s
access to and use of OpGen’s property, information, equipment and facilities. Consultant agrees to furnish OpGen with written reports
with respect to the Consulting Services if and when requested by OpGen.
1.2
Third Party Confidential Information. Consultant agrees not to use any trade secrets or other
confidential information of any other person, firm, corporation, institution or other entity in connection with any of the Consulting
Services.
1.3
No Conflicts. Consultant is under no contractual or other obligation or restriction which
is inconsistent with Consultant’s execution of this Agreement or the performance of the Consulting Services. During the Term (defined
below), Consultant will not enter into any agreement, either written or oral, in conflict with Consultant’s obligations under this
Agreement. Consultant will arrange to provide the Consulting Services in such manner and at such times that the Consulting Services will
not conflict with Consultant’s responsibilities under any other agreement, arrangement or understanding or pursuant to any employment
relationship Consultant has at any time with any third party.
1.4
Compliance with Policies. Consultant agrees to comply with all of the Company’s policies
and standards, as the Company may adopt from time to time, that are applicable to the Consultant, including without limitation, code of
ethics and business conduct and insider trading policies.
1.5
Absence of Debarment and other Disqualification. Consultant agrees and represents that neither
Consultant nor any Consultant Personnel (defined below) has (have) been debarred, and to the best of Consultant’s knowledge, is
(are) not under consideration to be debarred, by the U.S. Food and Drug Administration from working in or providing consulting services
to any pharmaceutical or biotechnology company under the Generic Drug Enforcement Act of 1992.
1.6
Other Representations and Warranties. Consultant represents and warrants that: (i)
Consultant has full right and power to enter into and perform this Agreement without the consent of any third party; (ii) Consultant will
comply with all laws and regulations applicable to Consultant’s obligations under this Agreement, will refrain from any unethical
conduct, and will maintain high standards of professionalism; and (ii) should OpGen permit Consultant to use any of OpGen’s equipment,
or facilities during the term of this Agreement, such permission shall be gratuitous and Consultant (a) shall be responsible for any injury
to any person (including death) or damage to property arising out of use of such equipment or facilities; and (b) shall perform all services
during OpGen’s normal business hours, unless OpGen otherwise specifically requests.
2.
Compensation. In consideration for the Consulting Services rendered by Consultant to OpGen,
OpGen agrees to pay Consultant the fees set forth in the Business Terms Exhibit attached hereto. Unless otherwise specified in the Business
Terms Exhibit, undisputed payments will be made by OpGen within thirty (30) days from OpGen’s receipt of Consultant’s complete
invoice. Invoices will contain such detail as OpGen may reasonably require and will be payable in U.S. Dollars in accordance with the
terms of the Business Terms Exhibit. OpGen will reimburse Consultant for reasonable and documented business expenses incurred by Consultant
in the performance of the Consulting Services as specified in the Business Terms Exhibit.
3.
Inventions.
3.1
Definition. “Inventions” means all inventions, discoveries, improvements,
ideas, designs, processes, products, computer programs, works of authorship, databases, mask works, trade secrets, know-how, research
and creations (whether or not patentable or subject to copyright or trade secret protection) that Consultant makes, conceives or reduces
to practice, either alone or jointly with others, and that (i) result from the performance of the Consulting Services, and/or (ii) result
from use of facilities, equipment, supplies, Research Materials (defined below), or Confidential Information (defined below) of OpGen.
3.2
Ownership. Consultant will promptly disclose all Inventions in confidence to OpGen. All Inventions
will be the exclusive property of OpGen. For purposes of the copyright laws of the United States, all Inventions will constitute “works
made for hire”, except to the extent such Inventions cannot by law be works made for hire. To the extent Inventions have not
been previously assigned to OpGen, Consultant hereby assigns and, to the extent any such assignment cannot be made at present, hereby
agrees to assign to OpGen, without further compensation, all right, title and interest in and to all Inventions and any and all related
patents, patent applications, copyrights, copyright applications, trademarks, trade names, trade secrets and other proprietary rights
in the United States and throughout the world. Consultant retains no rights to use the Inventions and agrees not to challenge the validity
of OpGen’s ownership in the Inventions. If Consultant has any right to the Inventions that cannot be assigned to OpGen by Consultant,
Consultant unconditionally and irrevocably grants to OpGen during the term of such rights, an exclusive, even as to Consultant, irrevocable,
perpetual, worldwide, fully paid and royalty-free license, with rights to sublicense through multiple levels of sublicensees, to reproduce,
make derivative works of, distribute, publicly perform and publicly display in any form or medium, whether now known or later developed,
make, use, sell, import, offer for sale and exercise any and all such rights. If Consultant has any rights to the Inventions that cannot
be assigned or licensed to OpGen, Consultant unconditionally and irrevocably waives the enforcement of such rights, and all claims and
causes of action of any kind against OpGen, an OpGen affiliate or licensee or related to OpGen’s customers, with respect to such
rights, and agrees, at OpGen’s request and expense, to consent to and join in any action to enforce such rights.
3.3
Assistance. Consultant agrees to assist OpGen in every way, both during and after the term
of this Agreement, to obtain and enforce United States and foreign intellectual property rights relating to Inventions in all countries.
In the event OpGen is unable to secure Consultant’s signature on any document needed in connection with such purposes, Consultant
hereby irrevocably designates and appoints OpGen and its duly authorized officers and agents as its agent and attorney in fact, which
appointment is coupled with an interest, to act on its behalf to execute and file any such documents and to do all other lawfully permitted
acts to further such purposes with the same legal force and effect as if executed by Consultant.
3.4
Research Materials. For Consulting Services which involve laboratory work or experiments,
“Research Materials” means all materials (i) furnished by OpGen, (ii) developed by Consultant in connection with the
Consulting Services, or (iii) the cost of which are reimbursed to Consultant by OpGen. Research Materials include, in the case of biological
materials, all progeny and unmodified derivatives of those materials, and in the case of chemical materials, all analogs, formulations,
mixtures and compositions of those materials. Research Materials are the sole property of OpGen. Consultant agrees not to use or evaluate
Research Materials for any purpose other than as directed by OpGen, nor transfer the Research Materials to any third party without the
prior consent of OpGen. Consultant will use the Research Materials in compliance with all laws and regulations.
3.5
Records. Consultant shall make and maintain adequate and current written records of all Inventions,
which records shall be available to and remain the property of OpGen at all times.
3.6
Agreement with Institution. This Agreement is made subject to the understanding that Consultant,
if affiliated with an Institution, may be required to fulfill certain obligations, including teaching, directing laboratory operations,
conducting research, and publishing work. It is further understood that Consultant may have signed an agreement concerning inventions
with Institution, under which Consultant may be obligated to assign to Institution certain inventions which arise out of or otherwise
relate to Consultant’s work at or for Institution or from Consultant’s use of certain of its facilities or intellectual property.
In performing the Consulting Services, Consultant agrees not to utilize Institution facilities or intellectual property if the result
of such use is that any Inventions will not be assignable solely to OpGen. Use of Institution’s telephone, fax machines or computers
for communication purposes, however, will not constitute use of Institution’s facilities under this Agreement.
3.7
Work at Third Party Facilities. Consultant agrees not to make any use of any funds, space,
personnel, facilities, equipment or other resources of a third party in performing the Consulting Services nor take any other action that
would result in a third party owning or having a right in any Inventions, unless agreed upon in writing in advance by OpGen.
4.
Confidential Information.
4.1
Definition. “Confidential Information” means any and all information disclosed
by OpGen to Consultant, or otherwise obtained by Consultant pursuant to services provided under this Agreement that is not generally known
in the Consultant’s trade or industry and shall include, without limitation, information with respect to the facilities and methods
of OpGen, Research Materials, trade secrets, Inventions, systems, patents and patent applications, procedures, manuals, confidential reports,
financial information, business plans, prospects, or opportunities, personnel information, lists of customers and suppliers, and information
of third parties provided by OpGen to Consultant. Confidential Information does not include information which (i) is in the public domain
or which becomes part of the public domain through no wrongful act on Consultant’s part but only after it becomes so publicly known,
(ii) is already in Consultant’s possession at the time of disclosure by OpGen, other than by previous disclosure by OpGen, as evidenced
by written or electronic records, or (iii) that becomes known to Consultant through disclosure by a third party having the right to disclose
the information, as evidenced by written or electronic records.
4.2
Obligations of Confidentiality. Consultant will not directly or indirectly publish, disseminate
or otherwise disclose, use for Consultant’s own benefit or for the benefit of a third party, deliver or make available to any third
party, any Confidential Information, other than in furtherance of the purposes of this Agreement, and only then with the prior written
consent of OpGen. If required, Consultant may disclose the Confidential Information to a governmental authority or by order of a court
of competent jurisdiction, provided that such disclosure is subject to all applicable governmental or judicial protection available for
like material and reasonable advance notice is given to OpGen. Consultant will exercise all reasonable precautions to physically protect
the integrity and confidentiality of the Confidential Information and will not remove any Confidential Information or copies thereof from
OpGen’s premises except to the extent necessary to fulfill the Consulting Services, and then only with OpGen’s prior consent.
Consultant may disseminate or permit access to Confidential Information only to Consultant Personnel who have a need to know such Confidential
Information in the course of the performance of their duties under this Agreement and who are bound to protect the confidentiality of
the Confidential Information consistent with the terms of this Agreement. OpGen will be entitled to seek injunctive relief as a remedy
for any breach of the terms of this Section 4.
5.
Restrictions. While Consultant is engaged by OpGen and for a period of eighteen (18) months
after the termination or cessation of the engagement for any reason, Consultant will not (i) provide consulting services to any business
or entity developing a product or sponsoring a project which competes with a product being developed or project being sponsored by OpGen
and for which Consultant is providing Consulting Services. It will not be considered a competitive activity for Consultant to be a member
of the faculty or staff of a university, college or other educational or non-profit research institution, nor (ii) recruit, solicit or
hire any consultants of OpGen or any person who was a consultant of OpGen during the twelve (12) month period prior to the termination
of Consultant’s engagement by OpGen, or induce or attempt to induce any of OpGen’s employees to terminate their employment
with, or otherwise cease their relationship with, OpGen or accept employment with anyone else.
6.
Publication. Consultant agrees to submit to OpGen a copy of any proposed manuscript or other
materials to be published or otherwise publicly disclosed which contain information or any discussion relating to OpGen or the Consulting
Services, in sufficient time in advance of such disclosure, to enable OpGen to determine if patentable Inventions or any Confidential
Information of OpGen would be disclosed. Consultant will cooperate with OpGen in this respect and will delete from the manuscript or other
disclosure any Confidential Information if requested by OpGen, and will assist OpGen in filing for patent protection for any patentable
Inventions prior to publication or other disclosure.
7.
Term and Termination.
7.1
Term. This Agreement will commence on the Effective Date and continue for the term specified
on the Business Terms Exhibit (the “Term”), unless sooner terminated pursuant to the express terms of this Section
7 or extended by mutual agreement of the parties.
7.2
Termination. Any party may terminate this Agreement at any time without cause upon thirty
(30) days’ prior written notice.
7.3
Termination for Breach. If either party breaches in any material respect any of its material
obligations under this Agreement, in addition to any other right or remedy the non-breaching party may have, the non-breaching party may
(i) terminate this Agreement effective immediate if the breach was not cured within fifteen (15) days after receipt of written notice
of the breach or (ii) immediately at any time upon written notice in the event of a material breach which cannot be cured (i.e.
breach of confidentiality obligation).
7.4
Effect of Expiration/Termination. Upon expiration or termination, neither OpGen nor Consultant
will have any further obligations under this Agreement, except (i) the liabilities accrued through the date of termination, and (ii) the
obligations under sections 3, 4, 5, 6, 7 and 8 will survive. Upon expiration or termination, and in any case upon OpGen’s request,
Consultant will at the sole discretion of OpGen either destroy or return immediately to OpGen all tangible Confidential Information, including
all copies and reproductions thereof, except for one (1) copy which may be retained solely for archival purposes.
8.
Miscellaneous.
8.1
Independent Contractor. All Consulting Services will be rendered by Consultant as an independent
contractor and this Agreement does not create an employer-employee relationship between OpGen and Consultant. Consultant will have no
rights to receive any employee benefits, such as health and accident insurance, sick leave or vacation which are accorded to regular OpGen
employees. Consultant will not in any way represent himself to be an employee, partner, joint venturer, or agent of OpGen. Consultant
is not authorized to make any representation, contract, or commitment on behalf of OpGen.
8.2
Taxes. Consultant will pay all required taxes on Consultant’s income from OpGen under
this Agreement. Consultant agrees to accept exclusive liability for complying with all applicable state and federal laws, including laws
governing self-employed individuals, if applicable, such as laws related to payment of taxes, social security, disability, and other contributions
based on fees paid to Consultant under this Agreement. OpGen will not withhold or make payments for social security, unemployment insurance
or disability insurance contributions, or obtain workers’ compensation insurance on Consultant’s behalf. Consultant will provide
OpGen with Consultant’s taxpayer identification number or social security number, as applicable.
8.3
Use of Name. Consultant consents to the use by OpGen of Consultant’s name and likeness
in written materials and oral presentations to current or prospective customers, partners, investors or others, provided that such materials
or presentations accurately describe the nature of Consultant’s relationship with or contribution to OpGen.
8.4
Assignability and Binding Effect. The Consulting Services to be rendered by Consultant are
personal in nature. Consultant may not assign or transfer this Agreement or any of Consultant’s rights or obligations hereunder
except to a corporation of which Consultant is the sole stockholder. In no event will Consultant assign or delegate responsibility for
actual performance of the Consulting Services to any other natural person except to Consultant Personnel as provided for under this Agreement.
This Agreement will be binding upon and inure to the benefit of the parties and their respective legal representatives, heirs, successors
and permitted assigns. OpGen may assign this Agreement to any other corporation or entity which acquires (whether by purchase, merger,
consolidation or otherwise) all or substantially all of the business and/or assets of OpGen.
8.5
Headings. The section headings are included solely for convenience of reference and will not
control or affect the meaning or interpretation of any of the provisions of this Agreement.
8.6
Notices. Any notices or other communications from one party to the other will be in writing
and will be given by addressing the same to the other at the address or facsimile number set forth in this Agreement. Notices to OpGen
will be marked “Attention: Chief Executive Officer”. Notice will be deemed to have been duly given when (i)
deposited in the United States mail with proper postage for first class registered or certified mail prepaid, return receipt requested,
(ii sent by any reputable commercial courier, delivery confirmation requested, (iii) delivered personally, or (iv) if promptly confirmed
by mail or commercial courier as provided above, when dispatched by facsimile.
8.7
No Modification. This Agreement may be changed only by a writing signed by authorized representatives
of both parties.
8.8
Severability. In the event that any one or more of the
provisions contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity,
illegality or unenforceability will not affect any other provisions of this Agreement, and all other provisions will remain in full
force and effect. If any provision of this Agreement is held to be excessively broad, it will be reformed and construed by limiting and
reducing it so as to be enforceable to the maximum extent permitted by law.
8.9
Entire Agreement. This Agreement constitutes the entire agreement of the parties with regard
to its subject matter, and supersedes all previous written or oral representations, agreements and understandings between the parties.
8.10
Governing Law. This Agreement will be governed by, and construed and enforced in accordance
with, the laws of the Federal Republic of Germany applicable to contracts made and to be performed therein, without giving effect to the
principles thereof relating to the conflict of laws.
8.11
Remedies. Consultant agrees that in addition to any other rights and remedies available to
OpGen for any breach or threatened breach by Consultant of Consultant’s obligations hereunder, OpGen will be entitled to enforcement
of Consultant’s obligations hereunder by whatever means are at OpGen’s disposal, including court injunction.
8.12
Counterparts. This Agreement may be executed in any number of counterparts, each of which
will be deemed an original, but all of which together will constitute one and the same instrument.
- Signatures on next page –
IN WITNESS WHEREOF, the parties hereto
have duly executed this Agreement under seal as of the Effective Date.
OpGen, Inc. |
Consultant/Entity:
|
/s/ William Rhodes
__________________________________________
Signature:
|
/s/ Johannes Bacher
__________________________________________
Signature:
|
William Rhodes, Chairman |
Printed Name: Johannes Bacher |
/s/ Oliver Schacht
_________________________________________
Signature:
Oliver Schacht, President & CEO |
|
January 8, 2024
__________________________________________
Date |
January 8, 2024
__________________________________________
Date |
|
Address: [**] |
|
________________________________________
Mobile:
[**]
__________________________________________
|
|
Facimile: NA
|
|
|
INSTITUTION
ACKNOWLEDGEMENT
AND CONSENT FORM
OpGen, Inc. (“OpGen”)
is prepared to enter into the foregoing Agreement with the consultant named on the preceding signature page (“Consultant”).
OpGen recognizes that as a member of the institution named below (“Institution”), Consultant is responsible for ensuring that
any consulting agreement Consultant enters into with a for-profit entity is not in conflict with the patent, consulting or other policies
of Institution. The proposed Agreement requires Consultant, if required by Institution policies, to disclose the proposed Agreement to
Institution and/or to obtain Institution’s consent to enter into the proposed Agreement.
Institution hereby acknowledges and
consents to Consultant entering into the foregoing Agreement.
INSTITUTION:
By ____________________
Print Name ____________________
Title
____________________
Date ____________________
v3.23.4
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
OpGen (NASDAQ:OPGN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024